Related Experiment Video
Updated: Jan 20, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Alcohol septal ablation in patients with concomitant hypertrophic cardiomyopathy and aortic valvular stenosis
Bassim El-Sabawi1, Rick A Nishimura2, Mayra E Guerrero2
1Department of Medicine, Mayo Clinic, Rochester, Minnesota.
Insights
Percutaneous alcohol septal ablation effectively reduces dynamic left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy and aortic stenosis. This minimally invasive procedure offers early symptom improvement for select patients.
Area of Science:
- Cardiology
- Interventional Cardiology
- Cardiac Surgery
Background:
- Alcohol septal ablation is established for hypertrophic cardiomyopathy-related dynamic left ventricular outflow tract (LVOT) obstruction.
- The efficacy of this procedure in patients with coexisting aortic stenosis (AS) is not well-defined.
Observation:
- A case series of six patients with severe dynamic LVOT obstruction and AS underwent alcohol septal ablation.
- Patients presented with NYHA class III or greater symptoms.
Findings:
- All patients successfully underwent alcohol septal ablation, achieving immediate reduction in the dynamic LVOT gradient.
- A residual fixed obstruction due to AS persisted post-ablation.
- At one-month follow-up, a majority of patients showed improvement in NYHA class.
Implications:
- Alcohol septal ablation appears feasible for managing combined dynamic LVOT obstruction and AS.
- Further research is needed to establish the optimal treatment strategy for this complex patient group.
Objective:
To describe the hemodynamic and early clinical outcomes of percutaneous alcohol septal ablation in patients with concomitant dynamic left ventricular outflow tract (LVOT) obstruction and aortic valvular stenosis (AS).
Background:
Alcohol septal ablation is an established method to relieve dynamic LVOT obstruction in patients with hypertrophic cardiomyopathy (HCM). However, the feasibility, safety, and efficacy of alcohol septal ablation in patients with serial obstructions from HCM and AS remain unclear.
Methods:
In this case series, we describe the early outcomes of alcohol septal ablation in six patients with significant dynamic LVOT obstruction and AS. All patients had evidence of severe dynamic LVOT obstruction (resting or provoked gradient ≥50 mmHg), mild to severe AS, and NYHA class III symptoms or greater.
Results:
Four (66.7%) patients had septal ablation performed in the setting of concomitant native valvular AS and two (33.3%) patients had TAVR performed prior to septal ablation. Successful alcohol septal ablation was performed in all patients and was associated with an immediate reduction of the dynamic LVOT gradient with a residual fixed obstruction related to AS. Four (66.7%) patients had follow-up at 1 month and of these, three (75%) had NYHA Class I-II symptoms and one (25%) Class III.
Conclusions:
Alcohol septal ablation is a feasible method of relieving dynamic LVOT obstruction in patients with concomitant HCM and AS. Further study is required to determine the optimal treatment approach in these patients.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy VI: Nursing Management
Cardiomyopathy V: Interprofessional Care

